Table 1 Comparison between the present study and previous PPS studies (4,5)
Ciofi Degli Atti et al. (4) | De Luca et al. (5) | Present study | |
|---|---|---|---|
Overall | |||
Year | June 2007 | October–December 2012 | February – December 2016 |
Number of PPSs | 1 | 1 | 3 |
Participating hospitals | 1 | 7 | 4 |
Percentage of patients with an ongoing AMs** prescription | 43.9% | 38.9% | 40% |
Mean prescription/treated patient | 1.4 | 1.56 | 1.32 |
Combination therapy/treated patients | 43.8% | 41.3% | 41.9% |
AMs prescribed empirically | 51% | – | 72.6% |
AMs use in Neonates | |||
Percentage of neonates receiving AMs | -* | 17.3% | 16.4% |
AMs used for prophylaxis | – | 62.8% | 59.4% |
AMs used for treatment | – | 37.2% | 40.6% |
Most common reason for treatment | – | Sepsis | Sepsis |
Top two prescribed AMs | – | Penicillins | Aminoglycosides |
Aminoglycosides | Ampicillin | ||
AMs use in Children | |||
Percentage of children receiving AMs | – | 47% | 51.8% |
AMs used for prophylaxis | – | 35.5% | 21.3% |
AMs used for treatment | – | 64.4% | 78.7% |
Most common reason for treatment | – | LRTI | LRTI |
Top two prescribed AMs | Third generation cephalosporins | Third generation cephalosporins | Third generation cephalosporins |
Penicilins plus enzyme inhibitor | Penicilins plus enzyme inhibitor | Penicilins plus enzyme inhibitor | |